Skip to content
Menu

XTL Biopharmaceuticals Ltd. XTLB

Full chart Compare
Set alert

Price alert · XTLB

All alert types
1.37 USD -0.08 (-5.84%)

Regular-session close

1.33 -0.04 -2.92%

After hours · Nov 20, 4:00 PM ET

1.37 Day range 1.59
1.37 52-week range 4.28
YTD
-40.95%
1 year
-57.72%

 

No chart data for this range yet.
Market cap
3.37M
EPS (ttm)
-0.36
Shares out
5.45M
YTD return
-40.95%
1-year return
-57.72%
50-day average
1.84
200-day average
2.32
Volume
1.78K
Avg volume
6.55K
Open
1.59
Previous close
1.46
Day's range
1.37 – 1.59
52-week range
1.37 – 4.28
Beta
1.00

Key statistics

Enterprise value
782.33M
Price / book
352.00
Total cash
2.34M
Return on equity
-13.07%

Fundamental scorecard

1 of 25 checks passed on XTLB’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Dec 31, 2025.

Financials — quick view

All financials
XTLB Revenue — annual 0
XTLB Net income — annual -6.97M
XTLB EPS — annual -3.20

Earnings

XTLB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 25, 2024Sep 1, 20240.00———
Oct 3, 2024Jun 1, 20240.00———
May 13, 2024Mar 1, 20240.000.10——
Nov 15, 2023Sep 1, 20230.00-0.04——
Aug 10, 2023Jun 1, 20230.00-0.07——

Upgrades / downgrades

XTLB analyst upgrades and downgrades
DateFirmActionFromTo
May 8, 2015HC Wainwright & Co.init—Buy

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
xtlbio.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on XTLB — it syncs with the Stock Master app.

Institution ownership

XTLB institution ownership
Holder% heldSharesValueReported
Noked Israel Ltd.3.65%198,888350.04KSep 29, 2024
Morgan Stanley0.49%26,45146.55KSep 29, 2024
Rhumbline Advisers0.12%6,51911.47KSep 29, 2024

Fund ownership

XTLB fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.16%8,90315.67KOct 30, 2024